Expertise in
10
conditions

Dr. John Nemunaitis

Internal Medicine
Office
3355 Glendale Ave Fl 3, 
Toledo, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Office
3355 Glendale Ave Fl 3, 
Toledo, OH 

Overview

John Nemunaitis is an Internal Medicine provider in Toledo, Ohio. Dr. Nemunaitis is highly rated in 10 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Ovarian Cancer, Melanoma, and Osteosarcoma.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 33 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
3355 Glendale Ave Fl 3, Toledo, OH 43614

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Phase IB Trial of Metformin, Digoxin, Simvastatin in Subjects With Advanced Pancreatic Cancer and Other Advanced Solid Tumors
Phase IB Trial of Metformin, Digoxin, Simvastatin in Subjects With Advanced Pancreatic Cancer and Other Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Metformin, Simvastatin, Digoxin
Study Phase: Phase 1
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer
Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 30, 2025
Intervention Type: Drug, Genetic
Study Drugs: Nab-paclitaxel, Gemcitabine
Study Phase: Phase 2
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: Pamiparib, Temozolomide
Study Phase: Phase 1
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drug: NBF-006
Study Phase: Phase 1
View 9 Less Clinical Trials

166 Total Publications

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Journal: JCO precision oncology
Published: January 14, 2026
Similar Doctors
Cem Akin
Expertise in
21
conditions
Dr. Cem Akin
Internal Medicine
Expertise in
21
conditions
Dr. Cem Akin
Internal Medicine

Domino's Farms

24 Frank Lloyd Wright Dr Ste 2100, Lobby H, 
Ann Arbor, MI 
 (49.4 miles away)
888-229-2409
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Akin completed his residency in Internal Medicine and PhD at the University of Louisville, and his Allergy/Immunology fellowship at the NIH Clinical Center, where he also worked as a staff physician and researcher. He was then an Assistant Professor at the University of Michigan and an Associate Professor at Harvard Medical School, where he established and lead the Mastocytosis Center at the Brigham and Women's Hospital in Boston. He is internationally recognized for his work on mast cell disorders and anaphylaxis and is an active member of the AAAAI. Dr. Akin is highly rated in 21 conditions, according to our data. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Anaphylaxis, Hereditary Alpha-Tryptasemia, and Tissue Biopsy.

Expertise in
20
conditions
Dr. Michael Kuhne
Internal Medicine
Expertise in
20
conditions
Dr. Michael Kuhne
Internal Medicine

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (46.4 miles away)
888-287-1082
Languages Spoken:
English
See accepted insurances

Michael Kuhne is an Internal Medicine provider in Ann Arbor, Michigan. Dr. Kuhne is highly rated in 20 conditions, according to our data. His top areas of expertise are Atrial Fibrillation, Fainting, Heart Block, Cardiac Ablation, and Pacemaker Implantation.

Rashmi Chugh
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception E, 
Ann Arbor, MI 
 (46.4 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rashmi Chugh is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma.

Frequently Asked Questions about Dr. John Nemunaitis

How do I make an appointment with Dr. John Nemunaitis?

You can book an appointment with Dr. John Nemunaitis by calling their office at 419-383-6644. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Nemunaitis a top-rated expert for Ewing Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Nemunaitis is classified as an Distinguished expert for Ewing Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Nemunaitis specialize in?

While Dr. John Nemunaitis is a Internal Medicine, they have specific expertise in Ewing Sarcoma, Ovarian Cancer, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. John Nemunaitis participate in research or clinical trials?

Yes. Dr. John Nemunaitis has published 166 articles and abstracts on conditions like Ewing Sarcoma. You can view a list of Dr. John Nemunaitis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nemunaitis's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile